Because our case report demonstrates that neither PD-L1-positive expression nor high TMB is required for a response to PD-1 inhibition-based immunotherapy, we advocate that patients with cutaneous angiosarcoma be considered for this therapy, given limited alternatives. This evidence concerns the gene CD274 and angiosarcoma.